Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer
Metrics: PDF 2110 views | HTML 2868 views | ?
Yan-Xiu Guo1,*, Kuang Hong Neoh2,*, Xiao-Hong Chang1, Yukun Sun2, Hong-Yan Cheng1, Xue Ye1, Rui-Qiong Ma1, Ray P.S. Han2 and Heng Cui1
1Center of Gynecologic Oncology, Peking University People’s Hospital, Beijing, China
2College of Engineering, Peking University, Beijing, China
*These authors contributed equally to this work
Ray P.S. Han, email: [email protected]
Heng Cui, email: [email protected]
Keywords: circulating tumor cells; microfluidic isolation; HE4; ovarian cancer; diagnosis
Received: July 21, 2017 Accepted: December 27, 2017 Published: January 04, 2018
Lacking a satisfactory screening test, ovarian cancer is frequently diagnosed at a late stage, leading to poor patient outcomes. This study investigated the diagnostic value of circulating tumor cells (CTCs) in peripheral blood from patients with suspected ovarian tumors. Sixty-one women suspected of having an ovarian mass were prospectively enrolled in this study. CTCs were identified and counted using microfluidic isolation and immunofluorescent staining of CD45, HE4, and epithelial and mesenchymal (E&M) markers (epithelial cell adhesion molecule, cytokeratins, and vimentin). Thirty (49%) of the patients were diagnosed with ovarian cancer. DAPI+/E&M+/CD45-/HE4+ CTC counts were higher in these patients than in patients with benign tumors (p = 0.016). The receiver operating characteristic (ROC) curve showed that the sensitivity of CTCs was 73.3%, which was superior to that of CA125 (56.7%). In patients with elevated CA125 levels (≥35 U/ml), CTC counts still showed good specificity (86.7%). Our findings suggest the DAPI+/E&M+/CD45-/HE4+ CTC count is a useful diagnostic indicator in patients with suspected ovarian cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.